Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 2
2017 1
2018 1
2020 3
2021 1
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Single-Cell Analysis Reveals Transcriptomic Features of Drug-Tolerant Persisters and Stromal Adaptation in a Patient-Derived EGFR-Mutated Lung Adenocarcinoma Xenograft Model.
Moghal N, Li Q, Stewart EL, Navab R, Mikubo M, D'Arcangelo E, Martins-Filho SN, Raghavan V, Pham NA, Li M, Shepherd FA, Liu G, Tsao MS. Moghal N, et al. Among authors: stewart el. J Thorac Oncol. 2023 Apr;18(4):499-515. doi: 10.1016/j.jtho.2022.12.003. Epub 2022 Dec 16. J Thorac Oncol. 2023. PMID: 36535627 Free article.
Sports neurology as a multidisciplinary field.
Stewart EL, Anderson SA, Williams VB. Stewart EL, et al. Handb Clin Neurol. 2018;158:11-18. doi: 10.1016/B978-0-444-63954-7.00002-1. Handb Clin Neurol. 2018. PMID: 30482338 Review.
Characterizing the last holdouts.
Stewart EL, Tsao MS. Stewart EL, et al. Oncotarget. 2017 Feb 21;8(8):12542-12543. doi: 10.18632/oncotarget.15090. Oncotarget. 2017. PMID: 28177913 Free PMC article. No abstract available.
Assessing therapy response in patient-derived xenografts.
Ortmann J, Rampášek L, Tai E, Mer AS, Shi R, Stewart EL, Mascaux C, Fares A, Pham NA, Beri G, Eeles C, Tkachuk D, Ho C, Sakashita S, Weiss J, Jiang X, Liu G, Cescon DW, O'Brien CA, Guo S, Tsao MS, Haibe-Kains B, Goldenberg A. Ortmann J, et al. Among authors: stewart el. Sci Transl Med. 2021 Nov 17;13(620):eabf4969. doi: 10.1126/scitranslmed.abf4969. Epub 2021 Nov 17. Sci Transl Med. 2021. PMID: 34788078
EGFR-mutated lung adenocarcinomas from patients who progressed on EGFR-inhibitors show high engraftment rates in xenograft models.
Martins-Filho SN, Weiss J, Pham NA, Li Q, Cabanero M, Fares A, Stewart EL, Shi R, Patel D, Pal P, McConnell J, Bradbury PA, Sacher AG, Leighl NB, Grindlay A, Allison F, Li M, Yasufuku K, Shepherd FA, Moghal N, Tsao MS, Liu G. Martins-Filho SN, et al. Among authors: stewart el. Lung Cancer. 2020 Jul;145:144-151. doi: 10.1016/j.lungcan.2020.03.022. Epub 2020 May 11. Lung Cancer. 2020. PMID: 32447118
Early Detection of Multiple Resistance Mechanisms by ctDNA Profiling in a Patient With EGFR-mutant Lung Adenocarcinoma Treated With Osimertinib.
Schmid S, Stewart EL, Martins-Filho SN, Cabanero M, Wang A, Bao H, Wu X, Patel D, Chen Z, Law JH, Bradbury PA, Shepherd FA, Leighl N, Tsao MS, Pugh T, Bratman SV, Sacher A, Liu G. Schmid S, et al. Among authors: stewart el. Clin Lung Cancer. 2020 Sep;21(5):e488-e492. doi: 10.1016/j.cllc.2020.03.009. Epub 2020 Apr 9. Clin Lung Cancer. 2020. PMID: 32389504 No abstract available.
Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma.
Stewart EL, Mascaux C, Pham NA, Sakashita S, Sykes J, Kim L, Yanagawa N, Allo G, Ishizawa K, Wang D, Zhu CQ, Li M, Ng C, Liu N, Pintilie M, Martin P, John T, Jurisica I, Leighl NB, Neel BG, Waddell TK, Shepherd FA, Liu G, Tsao MS. Stewart EL, et al. J Clin Oncol. 2015 Aug 1;33(22):2472-80. doi: 10.1200/JCO.2014.60.1492. Epub 2015 Jun 29. J Clin Oncol. 2015. PMID: 26124487